Background: The most severely disabled stroke patients are often excluded from studies evaluating effects of physiotherapy. This study intended to investigate the effect of an increased intensity of physiotherapy in combination with dexamphetamine the first week after ischemic stroke in patients with an impaired level of consciousness and severe motor dysfunction. Methods: Thirty patients were enrolled within 96 h after onset of symptoms. Patients were randomized to 30–45 min of physiotherapy twice daily or to maximally 15 min per day for 5 days. All patients received dexamphetamine to achieve alertness. Functional outcome measures were assessed at baseline, the day after treatment discontinuation, and 3 and 12 months after stroke onset. Residence of living was registered at long-term follow-ups. Results: No statistically significant differences were seen between groups in the outcomes measured at any time point. However, both groups improved over time in all outcomes at 3 and 12 months (p < 0.05), except for sensory functions at 3 months and motor functions at 12 months. The number of patients needed to treat (NNT) to achieve the desired improvement in Lindmark motor score was 8, with the 95% CI being NNT(harm) 10 to NNT(beneficial) 3. The fraction of patients who died was the same in both treatment groups, 47% (95% CI 28–65%). Conclusions: An increased intensity of physiotherapy in combination with dexamphetamine during the first week after stroke onset did not affect short- or long-term outcome in this limited sample of patients with severe stroke.

Keywords:
Cerebral infarction, Dextroamphetamine, Recovery of function, Rehabilitation
1.
Langhorne P, Wagenaar R, Partridge C: Physiotherapy after stroke: More is better? Physiother Res Int 1996;1:75–88.
2.
Kwakkel G, Wagenaar R, Koelman T, Lankhorst G, Koetsier J: Effects of intensity of stroke rehabilitation. A research synthesis. Stroke 1997;28:1550–1556.
3.
Kwakkel G, Wagenaar R, Twisk J, Lankhorst G, Koetsier J: Intensity of leg and arm training after primary middle artery stroke: A randomised controlled trial. Lancet 1999;354:191–197.
4.
Paolucci S, Antonucci G, Grasso MG, Morelli D, Troisi E, Coiro P, Bragoni M: Early versus delayed inpatient stroke rehabilitation: A matched comparison conducted in Italy. Arch Phys Med Rehabil 2000;81:695–700.
5.
Indredavik B, Bakke F, Slørdahl SA, Rokseth R, Håheim LL: Treatment in a combined acute and rehabilitation stroke unit. Which aspects are most important? Stroke 1999;30:917–923.
6.
Gladman JRF, Sackley CM: The scope for rehabilitation in severely disabled stroke patients. Disabil Rehabil 1998;20:391–394.
7.
Rang HP, Dale MM, Ritter JM: Pharmacology, ed 4. Edinburgh, Churchill Livingstone, 1999.
8.
Lindmark B, Hamrin E: Evaluation of functional capacity after stroke as a basis for active intervention. Presentation of a modified chart for motor capacity assessment and its reliability. Scand J Rehab Med 1988;20:103–109.
9.
Lindmark B, Hamrin E: Evaluation of functional capacity after stroke as a basis for intervention. Validation of a modified chart for motor capacity assessment. Scand J Rehab Med 1988;20:111–115.
10.
Stålhammar D, Starmark J-E, Holmgren E: The reaction level scale (RLS 85). Manual and guidelines. Acta Neurochir (Wien) 1988;91:12–20.
11.
Katz S, Ford A, Moskowitz R, Jackson B, Jaffe M: Studies of illness in the aged: The Index of ADL. A standardized measure of biological and psychosocial function. J Am Med Assoc 1963;185:914–919.
12.
WHO: Stroke – 1989. Recommendations on stroke prevention, diagnosis, and therapy. Stroke 1989;20:1407–1431.
13.
Goldstein L, Bertels C, Davis J: Interrater reliability of the NIH stroke scale. Arch Neurol 1989;46:660–662.
14.
Hamrin E, Wohlin A: Evaluation of the functional capacity of stroke patients through an activity index. Scand J Rehab Med 1982;14:93–100.
15.
Bamford J, Dennis M, Sandercock P, Burn J, Warlow C: The frequency, causes and timing of death within 30 days of a first stroke: The Oxfordshire Community Stroke Project. J Neurol Neurosurg Psychiatry 1990;53:824–829.
16.
Gelmers HJ, Gorter K, Weerdt CJD, Wiezer HJA: A controlled trial of nimodipine in acute ischemic stroke. N Engl J Med 1988;318:203–207.
17.
Altman DG: Confidence intervals for the number needed to treat. BMJ 1998;317:1309–1312.
18.
Barnes M, Ward AB: The value of rehabilitation; in Barnes M, Braithwaite B, Ward A (eds): Medical Aspects of Personal Injury Litigation. London, Blackwell Science, 1997, pp 17–46.
19.
Bamford J, Sandercock P, Dennis M, Burn J, Warlow C: Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991;337:1521–1524.
20.
Risedal A, Zeng J, Johansson B: Early training may exacerbate brain damage after focal brain ischemia in the rat. J Cereb Blood Flow Metab 1999;19:997–1003.
21.
Humm J, Kozlowski D, James D, Gotts J, Schallert T: Use-dependent exacerbation of brain damage occurs during an early post-lesion vulnerable period. Brain Res 1998;9:286–292.
22.
Crisostomo E, Duncan P, Propst M, Dawson D, Davis J: Evidence that amphetamine with physical therapy promotes recovery of motor function in stroke patients. Ann Neurol 1988;23:94–97.
23.
Martinsson L, Wahlgren NG: Safety of dexamphetamine in acute ischemic stroke – a randomized, double-blind, controlled, dose-escalation trial. Stroke 2003;34:475–481.
24.
Sonde L, Nordström M, Nilsson C, Lökk J, Viitanen M: A double-blind placebo-controlled study of the effects of amphetamine and physiotherapy after stroke. Cerebrovasc Dis 2001;12:253–257.
25.
Walker-Batson D, Smith P, Curtis S, Unwin H, Greenlee R: Amphetamine paired with physical therapy accelerates motor recovery after stroke. Further evidence. Stroke 1995;26:2254–2259.
© 2003 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.